MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- ORCHID PHARMA - MYLAN (US)
ORCHID PHARMA vs MYLAN (US) - Comparison Results
ORCHID PHARMA Change
Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 ORCHID PHARMA  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ORCHID PHARMA Sep-13 |
MYLAN Dec-18 |
ORCHID PHARMA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 194 | 3,589 | - | |
| Low | Rs | 35 | 1,975 | - | |
| Sales per share (Unadj.) | Rs | 276.5 | 1,651.5 | - | |
| Earnings per share (Unadj.) | Rs | -79.2 | 44.8 | - | |
| Cash flow per share (Unadj.) | Rs | -43.5 | 354.1 | - | |
| Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
| Dividend yield (eoy) | % | 0 | 0 | - | |
| Book value per share (Unadj.) | Rs | 53.9 | 1,786.6 | - | |
| Shares outstanding (eoy) | m | 70.45 | 514.50 | - | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 0.4 | 1.7 | 24.6% | |
| Avg P/E ratio | x | -1.4 | 62.0 | -2.3% | |
| P/CF ratio (eoy) | x | -2.6 | 7.9 | -33.5% | |
| Price / Book Value ratio | x | 2.1 | 1.6 | 136.3% | |
| Dividend payout | % | 0 | 0 | - | |
| Avg Mkt Cap | Rs m | 8,067 | 1,431,473 | 0.6% | |
| No. of employees | `000 | 2.8 | 35.0 | 8.0% | |
| Total wages/salary | Rs m | 2,527 | 0 | - | |
| Avg. sales/employee | Rs Th | 6,956.1 | 24,276.6 | 28.7% | |
| Avg. wages/employee | Rs Th | 902.5 | 0 | - | |
| Avg. net profit/employee | Rs Th | -1,993.0 | 659.2 | -302.3% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 19,477 | 849,683 | 2.3% | |
| Other income | Rs m | 407 | 0 | - | |
| Total revenues | Rs m | 19,884 | 849,683 | 2.3% | |
| Gross profit | Rs m | 1,103 | 219,866 | 0.5% | |
| Depreciation | Rs m | 2,519 | 159,094 | 1.6% | |
| Interest | Rs m | 5,227 | 40,867 | 12.8% | |
| Profit before tax | Rs m | -6,236 | 19,906 | -31.3% | |
| Minority Interest | Rs m | 20 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 511 | 0 | - | |
| Tax | Rs m | -125 | -3,167 | 4.0% | |
| Profit after tax | Rs m | -5,580 | 23,072 | -24.2% | |
| Gross profit margin | % | 5.7 | 25.9 | 21.9% | |
| Effective tax rate | % | 2.0 | -15.9 | -12.6% | |
| Net profit margin | % | -28.7 | 2.7 | -1,055.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 11,014 | 474,462 | 2.3% | |
| Current liabilities | Rs m | 32,060 | 345,935 | 9.3% | |
| Net working cap to sales | % | -108.1 | 15.1 | -714.4% | |
| Current ratio | x | 0.3 | 1.4 | 25.0% | |
| Inventory Days | Days | 95 | 84 | 113.5% | |
| Debtors Days | Days | 34 | 93 | 36.0% | |
| Net fixed assets | Rs m | 29,440 | 164,824 | 17.9% | |
| Share capital | Rs m | 705 | 452 | 155.7% | |
| Net worth | Rs m | 3,800 | 919,201 | 0.4% | |
| Long term debt | Rs m | 9,018 | 992,113 | 0.9% | |
| Total assets | Rs m | 46,510 | 2,465,655 | 1.9% | |
| Interest coverage | x | -0.2 | 1.5 | -13.0% | |
| Debt to equity ratio | x | 2.4 | 1.1 | 219.9% | |
| Sales to assets ratio | x | 0.4 | 0.3 | 121.5% | |
| Return on assets | % | -0.8 | 2.6 | -29.3% | |
| Return on equity | % | -146.9 | 2.5 | -5,850.6% | |
| Return on capital | % | -3.7 | 3.2 | -117.5% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,682 | 176,564 | 1.0% | |
| From Investments | Rs m | -9,860 | -91,264 | 10.8% | |
| From Financial Activity | Rs m | 6,644 | -82,254 | -8.1% | |
| Net Cashflow | Rs m | -1,535 | 1,463 | -104.9% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 75.4 Rs / USD
Compare ORCHID PHARMA With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare ORCHID PHARMA With: BIOCON WOCKHARDT SHASUN PHARMA ALKEM LABORATORIES DIVIS LABORATORIES
Today's Market
Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended lower.
Related Views On News
Most Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)
Apr 15, 2021Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
11x Bankruptcy to Bluechip Stock: A Rare India Revival Story (Profit Hunter)
Apr 16, 2021There is no stopping this 11-bagger stock from significant upside.
Top 3 Nifty ETFs to Buy Now (Fast Profits Daily)
Apr 20, 2021In this video I tell you the three Nifty ETFs I think are the best.
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
More
